Membranous Nephropathy Clinical Trials

• Confirmed diagnosis of PMN with positive anti-PLA2R antibodies

• CD19+ B cell count ≥40 cells/μL

• UPCR ≥2.0 g/g

• eGFR ≥35 mL/min/1.73 m²

• Stable RAAS inhibitor therapy

• Blood pressure \<150/90 mmHg at baseline

• Adequate hematologic, hepatic, and renal function

• Willing to use effective contraception (both sexes)

• Other inclusion criteria may apply